Dostarlimab for advanced dMMR/MSI cancers (not colorectal or endometrial)
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced (locally advanced or metastatic) and cannot be removed with surgery.
- You cannot have had any prior chemotherapy or other drugs for this advanced cancer (prior adjuvant therapy is okay if it ended over 6 months ago).
- Your tumor must have a specific genetic marker called dMMR or MSI-H, confirmed by a central lab.
- Your cancer must be one of the listed types: small bowel, stomach, pancreas, adrenal, unknown origin, neuroendocrine (high-grade), or soft tissue sarcoma (not GIST). It cannot be colorectal or endometrial.
- You must have at least one tumor that can be measured on scans, and be in good enough health to walk around and care for yourself (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called dostarlimab for people with a specific type of stomach cancer that has not spread. The goal is to see if the drug can make the tumor disappear, so you might not need surgery right away.
This trial tests a new immunotherapy drug (adebrelimab) combined with chemotherapy or another drug (SHR-8068) for a specific type of advanced stomach cancer that has a genetic marker called dMMR or MSI-H. The goal is to see if these combinations can make the tumor shrink enough to be removed with surgery.
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This trial tests a drug called dostarlimab (an immunotherapy) given before surgery for early-stage endometrial cancer that has a specific genetic feature (MMRd/MSI-H). The goal is to see if the drug can shrink or eliminate the cancer before standard surgery.
This trial tests different lengths of treatment with the drug dostarlimab for people with a specific type of rectal cancer that has a high number of genetic mutations. The goal is to find the best duration of treatment to improve outcomes.
Hear when a new Pancreatic Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.